Reduced	O
mitogenic	O
stimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
as	O
a	O
prognostic	O
parameter	O
for	O
the	O
course	O
of	O
breast	O
cancer	O
:	O
a	O
prospective	O
longitudinal	O
study	O
.	O

Immunosuppression	O
has	O
been	O
often	O
associated	O
with	O
the	O
course	O
of	O
malignant	O
diseases	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
proliferation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
with	O
phytohaemagglutinin	B-protein
(	O
PHA	B-protein
)	O
was	O
assessed	O
prospectively	O
in	O
90	O
patients	O
with	O
stage	O
I-III	O
breast	O
cancer	O
.	O

Whereas	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
preoperatively	O
was	O
significantly	O
decreased	O
when	O
compared	O
with	O
data	O
obtained	O
in	O
healthy	O
control	O
individuals	O
(	O
P	O
<	O
0.001	O
)	O
,	O
the	O
degree	O
of	O
the	O
defect	O
in	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
depended	O
upon	O
the	O
tumour	O
burden	O
as	O
manifested	O
by	O
tumour	O
size	O
and	O
axillary	O
lymph	O
node	O
involvement	O
(	O
P	O
<	O
0.003	O
in	O
each	O
case	O
)	O
.	O

PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
dropped	O
significantly	O
in	O
patients	O
who	O
received	O
adjuvant	O
chemotherapy	O
consisting	O
of	O
cyclophosphamide	O
,	O
methotrexate	O
and	O
fluorouracil	O
(	O
CMF	O
)	O
after	O
an	O
observation	O
period	O
of	O
6	O
months	O
(	O
P	O
<	O
0.01	O
)	O
,	O
but	O
not	O
in	O
patients	O
under	O
adjuvant	O
treatment	O
with	O
tamoxifen	O
only	O
.	O

After	O
an	O
additional	O
6	O
months	O
(	O
i.e.	O
12	O
months	O
after	O
surgery	O
)	O
,	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
was	O
similar	O
in	O
patients	O
after	O
adjuvant	O
chemotherapy	O
with	O
CMF	O
and	O
in	O
those	O
receiving	O
continued	O
adjuvant	O
tamoxifen	O
treatment	O
(	O
P	O
>	O
0.1	O
)	O
,	O
but	O
in	O
all	O
patients	O
still	O
significantly	O
decreased	O
as	O
compared	O
with	O
healthy	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
.	O

When	O
data	O
obtained	O
preoperatively	O
and	O
after	O
12	O
months	O
were	O
compared	O
,	O
it	O
was	O
found	O
that	O
out	O
of	O
23	O
patients	O
whose	O
PBMCs	B-cell_type
had	O
experienced	O
a	O
drop	O
in	O
their	O
PHA	B-protein
-induced	O
proliferation	O
,	O
14	O
(	O
61	O
%	O
)	O
had	O
developed	O
metastatic	O
disease	O
within	O
the	O
subsequent	O
24	O
months	O
(	O
i.e.	O
36	O
months	O
after	O
surgery	O
)	O
.	O

In	O
contrast	O
,	O
out	O
of	O
59	O
patients	O
whose	O
PBMCs	B-cell_type
showed	O
an	O
increase	O
in	O
their	O
PHA	B-protein
-induced	O
proliferation	O
within	O
the	O
first	O
12	O
months	O
after	O
surgery	O
,	O
only	O
one	O
(	O
2	O
%	O
)	O
presented	O
with	O
disease	O
progression	O
.	O

We	O
thus	O
conclude	O
that	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
depends	O
upon	O
the	O
tumour	O
load	O
and	O
is	O
a	O
good	O
clinical	O
predictor	O
for	O
the	O
further	O
course	O
of	O
the	O
disease	O
.	O

British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1995	NULL
)	NULL
71	NULL
,	NULL
1292-	NULL
12	NULL
%	NULL
©	NULL
1995	NULL
Stockton	NULL
Press	NULL
-	NULL
All	NULL
rights	NULL
reserved	NULL
0007-0920/95	NULL
$	NULL
12.00	NULL
Reduced	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
as	NULL
a	NULL
prognostic	NULL
parameter	NULL
for	NULL
the	NULL
course	NULL
of	NULL
breast	NULL
cancer	NULL
:	NULL
a	NULL
prospective	NULL
longitudinal	NULL
study	NULL
Ch	NULL
Wiltschke	NULL
'	NULL
.	NULL

M	NULL
Krainer	NULL
'	NULL
,	NULL
AC	NULL
Budinsky	NULL
'	NULL
,	NULL
A	NULL
Berger	NULL
,	NULL
Ch	NULL
Miller	NULL
.	NULL

,	NULL
R	NULL
Zeillinger®	NULL
,	NULL
P	NULL
Speiser	NULL
'	NULL
,	NULL
E	NULL
Kubista®	NULL
.	NULL

M	NULL
Eibl	NULL
and	NULL
CC	NULL
Zielinsk	NULL
'	NULL
'Clinical	NULL
Division	NULL
of	NULL
Oncology	NULL
.	NULL

Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
1	NULL
.	NULL

'Department	NULL
of	NULL
Obstetrics	NULL
and	NULL
Gynaecology	NULL
.	NULL

'Clinical	NULL
Division	NULL
of	NULL
Gastroenterology	NULL
and	NULL
Hepatology	NULL
.	NULL

Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
IV	NULL
,	NULL
and	NULL
*Institute	NULL
of	NULL
Immunology	NULL
.	NULL

University	NULL
of	NULL
Vienna	NULL
,	NULL
Austria	NULL
.	NULL

Summary	NULL
-	NULL
Immunosuppression	NULL
has	NULL
been	NULL
often	NULL
associated	NULL
with	NULL
the	NULL
course	NULL
of	NULL
malignant	NULL
diseases	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
the	NULL
proliferation	NULL
of	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
in	NULL
response	NULL
to	NULL
mitogenic	NULL
stimulation	NULL
with	NULL
phytohaemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
was	NULL
assessed	NULL
prospectively	NULL
in	NULL
90	NULL
patients	NULL
with	NULL
stage	NULL
I-III	NULL
breast	NULL
cancer	NULL
.	NULL

Whereas	NULL
PHA-induced	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
preoperatively	NULL
was	NULL
significantly	NULL
decreased	NULL
when	NULL
compared	NULL
with	NULL
data	NULL
obtained	NULL
in	NULL
healthy	NULL
control	NULL
individuals	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

the	NULL
degree	NULL
of	NULL
the	NULL
defect	NULL
in	NULL
PHA-induced	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
depended	NULL
upon	NULL
the	NULL
tumour	NULL
burden	NULL
as	NULL
manifested	NULL
by	NULL
tumour	NULL
size	NULL
and	NULL
axillary	NULL
lymph	NULL
node	NULL
involvement	NULL
(	NULL
2	NULL
<	NULL
0.003	NULL
in	NULL
each	NULL
case	NULL
)	NULL
.	NULL

PHA-induced	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
dropped	NULL
significantly	NULL
in	NULL
patients	NULL
who	NULL
received	NULL
adjuvant	NULL
chemotherapy	NULL
consisting	NULL
of	NULL
cyclophosphamide	NULL
.	NULL

methotrexate	NULL
and	NULL
fluorouracil	NULL
(	NULL
CMF	NULL
)	NULL
after	NULL
an	NULL
observation	NULL
period	NULL
of	NULL
6	NULL
months	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

but	NULL
not	NULL
in	NULL
patients	NULL
under	NULL
adjuvant	NULL
treatment	NULL
with	NULL
tamoxifen	NULL
only	NULL
.	NULL

After	NULL
an	NULL
additional	NULL
6	NULL
months	NULL
(	NULL
i.e	NULL
.	NULL

12	NULL
months	NULL
after	NULL
surgery	NULL
)	NULL
.	NULL

PHA-induced	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
was	NULL
similar	NULL
in	NULL
patients	NULL
after	NULL
adjuvant	NULL
chemotherapy	NULL
with	NULL
CMF	NULL
and	NULL
in	NULL
those	NULL
receiving	NULL
continued	NULL
adjuvant	NULL
tamoxifen	NULL
treatment	NULL
(	NULL
P	NULL
>	NULL
0.1	NULL
)	NULL
.	NULL

but	NULL
in	NULL
all	NULL
patients	NULL
still	NULL
significantly	NULL
decreased	NULL
as	NULL
compared	NULL
with	NULL
healthy	NULL
controls	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

When	NULL
data	NULL
obtained	NULL
preoperatively	NULL
and	NULL
after	NULL
12	NULL
months	NULL
were	NULL
compared	NULL
.	NULL

it	NULL
was	NULL
found	NULL
that	NULL
out	NULL
of	NULL
23	NULL
patients	NULL
whose	NULL
PBMCs	NULL
had	NULL
experienced	NULL
a	NULL
drop	NULL
in	NULL
their	NULL
PHA-induced	NULL
proliferation	NULL
.	NULL

14	NULL
(	NULL
61	NULL
%	NULL
)	NULL
had	NULL
developed	NULL
metastatic	NULL
disease	NULL
within	NULL
the	NULL
subsequent	NULL
24	NULL
months	NULL
(	NULL
ie	NULL
.	NULL

36	NULL
months	NULL
after	NULL
surgery	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
.	NULL

out	NULL
of	NULL
59	NULL
patients	NULL
whose	NULL
PBMCs	NULL
showed	NULL
an	NULL
increase	NULL
in	NULL
their	NULL
PHA-induced	NULL
proliferation	NULL
within	NULL
the	NULL
first	NULL
12	NULL
months	NULL
after	NULL
surgery	NULL
.	NULL

only	NULL
one	NULL
(	NULL
2	NULL
%	NULL
)	NULL
presented	NULL
with	NULL
disease	NULL
progression	NULL
.	NULL

We	NULL
thus	NULL
conclude	NULL
that	NULL
PHA-induced	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
depends	NULL
upon	NULL
the	NULL
tumour	NULL
load	NULL
and	NULL
is	NULL
a	NULL
good	NULL
clinical	NULL
predictor	NULL
for	NULL
the	NULL
further	NULL
course	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

Keywords	NULL
:	NULL
breast	NULL
cancer	NULL
.	NULL

lymphocyte	NULL
proliferation	NULL
:	NULL
prognosis	NULL
Several	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
patients	NULL
with	NULL
cancer	NULL
as	NULL
well	NULL
as	NULL
experimental	NULL
animals	NULL
with	NULL
transplanted	NULL
tumours	NULL
show	NULL
a	NULL
decrease	NULL
in	NULL
delayed-type	NULL
hypersensitivity	NULL
(	NULL
DTH	NULL
)	NULL
reactions	NULL
and	NULL
experience	NULL
cutaneous	NULL
anergy	NULL
(	NULL
Stein	NULL
et	NULL
al..	NULL
1976	NULL
;	NULL
Broder	NULL
and	NULL
Waldmann	NULL
.	NULL

1978	NULL
;	NULL
Giuliano	NULL
et	NULL
al..	NULL
1979	NULL
)	NULL
.	NULL

This	NULL
fact	NULL
was	NULL
attributed	NULL
to	NULL
an	NULL
induction	NULL
of	NULL
suppressor	NULL
cells	NULL
(	NULL
Kirchner	NULL
.	NULL

1978	NULL
:	NULL
Yu	NULL
er	NULL
al..	NULL
1977	NULL
;	NULL
North	NULL
and	NULL
Bursuker	NULL
.	NULL

1984	NULL
)	NULL
.	NULL

the	NULL
emergence	NULL
of	NULL
soluble	NULL
suppressive	NULL
factors	NULL
(	NULL
Whittaker	NULL
et	NULL
a/..	NULL
1971	NULL
;	NULL
Nimberg	NULL
et	NULL
al..	NULL
1975	NULL
;	NULL
North	NULL
ert	NULL
al..	NULL
1984	NULL
)	NULL
or	NULL
to	NULL
a	NULL
lack	NULL
of	NULL
lymphokines	NULL
(	NULL
Fearon	NULL
er	NULL
al..	NULL
1990	NULL
)	NULL
associated	NULL
with	NULL
the	NULL
development	NULL
of	NULL
neoplasms	NULL
.	NULL

Consequently	NULL
.	NULL

impressive	NULL
results	NULL
were	NULL
achieved	NULL
by	NULL
the	NULL
induction	NULL
of	NULL
lytic	NULL
effector	NULL
T-cell	NULL
function	NULL
by	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
.	NULL

leading	NULL
to	NULL
the	NULL
establishment	NULL
of	NULL
lymphokine-activated	NULL
killer	NULL
cell	NULL
therapy	NULL
in	NULL
patients	NULL
with	NULL
various	NULL
malignancies	NULL
.	NULL

Established	NULL
prognostic	NULL
markers	NULL
in	NULL
breast	NULL
cancer	NULL
include	NULL
mainly	NULL
tumour-associated	NULL
characteristics	NULL
such	NULL
as	NULL
the	NULL
number	NULL
of	NULL
involved	NULL
axillary	NULL
lymph	NULL
nodes	NULL
.	NULL

tumour	NULL
size	NULL
.	NULL

oestrogen	NULL
receptor	NULL
status	NULL
and	NULL
oncogene	NULL
overexpression	NULL
(	NULL
Clark	NULL
and	NULL
McGuire	NULL
.	NULL

1988	NULL
;	NULL
Contesso	NULL
et	NULL
al..	NULL
1989	NULL
)	NULL
.	NULL

but	NULL
no	NULL
immunological	NULL
characteristics	NULL
of	NULL
tumour	NULL
or	NULL
host	NULL
.	NULL

A	NULL
series	NULL
of	NULL
studies	NULL
have	NULL
been	NULL
performed	NULL
to	NULL
investigate	NULL
the	NULL
latter	NULL
aspect	NULL
(	NULL
Penn	NULL
.	NULL

1982	NULL
.	NULL

1988	NULL
:	NULL
Zielinski	NULL
et	NULL
a/..	NULL
1989a	NULL
;	NULL
Knogler	NULL
er	NULL
al..	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
these	NULL
studies	NULL
have	NULL
dealt	NULL
.	NULL

however	NULL
.	NULL

with	NULL
certain	NULL
functions	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
assessed	NULL
at	NULL
single	NULL
time	NULL
points	NULL
during	NULL
the	NULL
course	NULL
of	NULL
the	NULL
disease	NULL
and	NULL
are	NULL
thus	NULL
of	NULL
limited	NULL
value	NULL
.	NULL

as	NULL
both	NULL
.	NULL

chemo-	NULL
and	NULL
radiotherapy	NULL
can	NULL
exert	NULL
considerable	NULL
influence	NULL
upon	NULL
the	NULL
parameters	NULL
measured	NULL
(	NULL
Whittaker	NULL
er	NULL
a/..	NULL

Correspondence	NULL
:	NULL
CC	NULL
Zielinski	NULL
.	NULL

Clinical	NULL
Division	NULL
of	NULL
Oncology	NULL
.	NULL

Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
I	NULL
.	NULL

University	NULL
Hospital	NULL
.	NULL

Wahringer	NULL
Gurtel	NULL
18-20	NULL
.	NULL

A-1090	NULL
Vienna	NULL
.	NULL

Austria	NULL
Received	NULL
16	NULL
September	NULL
1994	NULL
;	NULL
revised	NULL
30	NULL
December	NULL
1994	NULL
;	NULL
accepted	NULL
5	NULL
January	NULL
1995	NULL
1971	NULL
;	NULL
Stein	NULL
er	NULL
al..	NULL
1976	NULL
;	NULL
Vose	NULL
and	NULL
Moore	NULL
.	NULL

1980	NULL
;	NULL
Uchida	NULL
and	NULL
Hoshino	NULL
.	NULL

1980	NULL
;	NULL
Cunningham-Rundles	NULL
er	NULL
al..	NULL
1981	NULL
;	NULL
White	NULL
et	NULL
al..	NULL
1982	NULL
;	NULL
Tichatschek	NULL
et	NULL
al..	NULL
1988	NULL
)	NULL
.	NULL

Moreover	NULL
.	NULL

many	NULL
of	NULL
the	NULL
studies	NULL
on	NULL
immune	NULL
function	NULL
in	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
have	NULL
utilised	NULL
sophisticated	NULL
methods	NULL
which	NULL
are	NULL
not	NULL
available	NULL
within	NULL
the	NULL
routine	NULL
clinical	NULL
setting	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
considera-tions	NULL
.	NULL

we	NULL
have	NULL
decided	NULL
to	NULL
study	NULL
prospectively	NULL
and	NULL
longitudinally	NULL
proliferative	NULL
responses	NULL
of	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
stimulated	NULL
with	NULL
phytohaemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
,	NULL
which	NULL
is	NULL
an	NULL
easily	NULL
applicable	NULL
.	NULL

widely	NULL
used	NULL
and	NULL
accepted	NULL
assay	NULL
giving	NULL
reproducible	NULL
and	NULL
easily	NULL
quantifiable	NULL
data	NULL
.	NULL

Results	NULL
from	NULL
these	NULL
experiments	NULL
were	NULL
correlated	NULL
with	NULL
tumour	NULL
status	NULL
and	NULL
the	NULL
course	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

We	NULL
report	NULL
that	NULL
the	NULL
initial	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
in	NULL
response	NULL
to	NULL
PHA	NULL
depended	NULL
upon	NULL
the	NULL
tumour	NULL
load	NULL
and	NULL
that	NULL
.	NULL

furthermore	NULL
.	NULL

the	NULL
longitudinal	NULL
assessment	NULL
of	NULL
PHA-induced	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
constituted	NULL
a	NULL
good	NULL
prognostic	NULL
marker	NULL
for	NULL
the	NULL
development	NULL
of	NULL
metastatic	NULL
disease	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Patients	NULL
and	NULL
clinical	NULL
variables	NULL
Ninety	NULL
female	NULL
patients	NULL
(	NULL
mean	NULL
age	NULL
54	NULL
+	NULL
2.3	NULL
years	NULL
)	NULL
were	NULL
included	NULL
in	NULL
this	NULL
study	NULL
.	NULL

The	NULL
patients	NULL
were	NULL
all	NULL
diagnosed	NULL
as	NULL
having	NULL
stage	NULL
I	NULL
(	NULL
eight	NULL
patients	NULL
)	NULL
.	NULL

II	NULL
(	NULL
53	NULL
patients	NULL
)	NULL
or	NULL
III	NULL
(	NULL
29	NULL
patients	NULL
)	NULL
breast	NULL
cancer	NULL
between	NULL
October	NULL
1988	NULL
and	NULL
December	NULL
1991	NULL
.	NULL

Patients	NULL
with	NULL
metastatic	NULL
(	NULL
ie	NULL
.	NULL

stage	NULL
IV	NULL
)	NULL
disease	NULL
were	NULL
excluded	NULL
from	NULL
the	NULL
study	NULL
.	NULL

After	NULL
surgery	NULL
.	NULL

all	NULL
patients	NULL
with	NULL
stage	NULL
II	NULL
and	NULL
III	NULL
disease	NULL
were	NULL
included	NULL
consecutively	NULL
in	NULL
a	NULL
clinical	NULL
treatment	NULL
protocol	NULL
of	NULL
adjuvant	NULL
therapy	NULL
randomising	NULL
between	NULL
treatment	NULL
with	NULL
either	NULL
cyclophosphamide	NULL
.	NULL

methotrexate	NULL
and	NULL
fluoruracil	NULL
(	NULL
CMF	NULL
:	NULL
Bonadonna	NULL
et	NULL
al..	NULL
1977	NULL
)	NULL
for	NULL
6	NULL
months	NULL
.	NULL

endocrine	NULL
treatment	NULL
with	NULL
tamoxifen	NULL
(	NULL
20	NULL
mg	NULL
daily	NULL
:	NULL
Mik	NULL
]	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
EBCTCG	NULL
,	NULL
1992	NULL
)	NULL
for	NULL
2	NULL
years	NULL
or	NULL
combined	NULL
chemotherapeutic	NULL
plus	NULL
endocrine	NULL
(	NULL
i.e	NULL
.	NULL

tamoxifen	NULL
)	NULL
treatment	NULL
.	NULL

Only	NULL
patients	NULL
>	NULL
70	NULL
years	NULL
were	NULL
excluded	NULL
from	NULL
the	NULL
treatment	NULL
protocol	NULL
with	NULL
all	NULL
others	NULL
being	NULL
treated	NULL
according	NULL
to	NULL
the	NULL
protocol	NULL
.	NULL

Adjuvant	NULL
treatment	NULL
started	NULL
within	NULL
3	NULL
weeks	NULL
after	NULL
surgery	NULL
.	NULL

Although	NULL
all	NULL
patients	NULL
with	NULL
stage	NULL
I-III	NULL
disease	NULL
received	NULL
radiotherapy	NULL
to	NULL
the	NULL
operated	NULL
breast	NULL
,	NULL
patients	NULL
with	NULL
stage	NULL
I	NULL
disease	NULL
did	NULL
not	NULL
receive	NULL
any	NULL
further	NULL
adjuvant	NULL
treatment	NULL
with	NULL
either	NULL
CMF	NULL
or	NULL
tamoxifen	NULL
.	NULL

Collection	NULL
of	NULL
blood	NULL
samples	NULL
Blood	NULL
samples	NULL
were	NULL
collected	NULL
by	NULL
venous	NULL
puncture	NULL
into	NULL
tubes	NULL
containing	NULL
preservative-free	NULL
heparin	NULL
before	NULL
surgery	NULL
and	NULL
3	NULL
and	NULL
12	NULL
months	NULL
after	NULL
surgery	NULL
or	NULL
follow-up	NULL
.	NULL

The	NULL
time	NULL
point	NULL
of	NULL
12	NULL
months	NULL
after	NULL
surgery	NULL
equalled	NULL
6	NULL
months	NULL
after	NULL
termination	NULL
of	NULL
adjuvant	NULL
chemotherapy	NULL
in	NULL
patients	NULL
who	NULL
had	NULL
received	NULL
CMF	NULL
.	NULL

For	NULL
the	NULL
collection	NULL
of	NULL
sera	NULL
,	NULL
blood	NULL
was	NULL
drawn	NULL
into	NULL
tubes	NULL
which	NULL
did	NULL
not	NULL
contain	NULL
any	NULL
addition	NULL
.	NULL

Controls	NULL
PBMCs	NULL
from	NULL
60	NULL
and	NULL
sera	NULL
from	NULL
six	NULL
healthy	NULL
age-matched	NULL
females	NULL
(	NULL
mean	NULL
age	NULL
55	NULL
+	NULL
3.2	NULL
years	NULL
)	NULL
served	NULL
as	NULL
controls	NULL
.	NULL

Pathological	NULL
and	NULL
biochemical	NULL
analysis	NULL
of	NULL
tissue	NULL
samples	NULL
Pathological	NULL
diagnosis	NULL
was	NULL
made	NULL
on	NULL
paraffin-embedded	NULL
specimens	NULL
of	NULL
tissue	NULL
obtained	NULL
during	NULL
surgery	NULL
using	NULL
routine	NULL
methods	NULL
.	NULL

Hormone	NULL
receptor	NULL
status	NULL
was	NULL
assessed	NULL
by	NULL
biochemical	NULL
means	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Zielinski	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
19894	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
PBMCs	NULL
were	NULL
gained	NULL
by	NULL
centrifugation	NULL
of	NULL
whole	NULL
heparinised	NULL
venous	NULL
blood	NULL
over	NULL
a	NULL
Ficoll-Hypaque	NULL
(	NULL
Ficoll-Paque	NULL
,	NULL
Phar-macia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
density	NULL
gradient	NULL
and	NULL
subsequently	NULL
resuspended	NULL
in	NULL
RPMI-1640	NULL
(	NULL
Gibco	NULL
)	NULL
supplemented	NULL
with	NULL
100	NULL
IU	NULL
of	NULL
penicillin	NULL
and	NULL
100	NULL
ug	NULL
ml-	NULL
'	NULL
streptomycin	NULL
and	NULL
adjusted	NULL
to	NULL
1	NULL
x	NULL
10°	NULL
PBMCs	NULL
ml-	NULL
'	NULL
.	NULL

Mitogenic	NULL
stimulation	NULL
with	NULL
PHA	NULL
Cell	NULL
cultures	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
White	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
1	NULL
x	NULL
10°	NULL
PBMCs	NULL
suspended	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
RPMI-1640	NULL
were	NULL
pipetted	NULL
into	NULL
microtitre	NULL
plates	NULL
and	NULL
PHA	NULL
added	NULL
to	NULL
final	NULL
concentrations	NULL
of	NULL
10	NULL
ug	NULL
ml~	NULL
'	NULL
,	NULL
50	NULL
ug	NULL
ml~	NULL
'	NULL
and	NULL
100	NULL
ug	NULL
ml~	NULL
'	NULL
respectively	NULL
.	NULL

All	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
for	NULL
each	NULL
patient	NULL
and	NULL
for	NULL
each	NULL
PHA	NULL
concentration	NULL
.	NULL

Healthy	NULL
age-matched	NULL
females	NULL
served	NULL
as	NULL
controls	NULL
to	NULL
circumvent	NULL
a	NULL
possible	NULL
influence	NULL
of	NULL
steroids	NULL
through	NULL
changes	NULL
in	NULL
the	NULL
pool	NULL
size	NULL
of	NULL
radioactivity	NULL
.	NULL

The	NULL
cultures	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
containing	NULL
5	NULL
%	NULL
carbon	NULL
dioxide	NULL
for	NULL
a	NULL
total	NULL
of	NULL
96	NULL
h.	NULL
Sixteen	NULL
hours	NULL
before	NULL
the	NULL
end	NULL
of	NULL
the	NULL
incubation	NULL
period	NULL
,	NULL
100	NULL
ul	NULL
of	NULL
supplemented	NULL
medium	NULL
containing	NULL
20	NULL
ul	NULL
of	NULL
[	NULL
'HJthymidine	NULL
(	NULL
185	NULL
GBq	NULL
mmol~	NULL
'	NULL
;	NULL
Amersham	NULL
,	NULL
UK	NULL
)	NULL
was	NULL
added	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
with	NULL
an	NULL
automatic	NULL
harvester	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
radioactivity	NULL
was	NULL
determined	NULL
by	NULL
liquid	NULL
scintillation	NULL
in	NULL
a	NULL
beta	NULL
counter	NULL
.	NULL

In	NULL
order	NULL
to	NULL
analyse	NULL
the	NULL
influence	NULL
of	NULL
sera	NULL
of	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
upon	NULL
lymphocyte	NULL
proliferation	NULL
,	NULL
PBMCs	NULL
derived	NULL
from	NULL
healthy	NULL
individuals	NULL
were	NULL
preincubated	NULL
with	NULL
sera	NULL
diluted	NULL
1:10	NULL
or	NULL
1:100	NULL
(	NULL
v/v	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
at	NULL
37°C	NULL
for	NULL
3	NULL
h	NULL
and	NULL
submitted	NULL
subsequently	NULL
to	NULL
PHA	NULL
assays	NULL
as	NULL
above	NULL
.	NULL

Characterisation	NULL
of	NULL
suppressive	NULL
factors	NULL
in	NULL
sera	NULL
Sera	NULL
were	NULL
obtained	NULL
from	NULL
(	NULL
i	NULL
)	NULL
six	NULL
healthy	NULL
controls	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
from	NULL
nine	NULL
patients	NULL
with	NULL
metastatic	NULL
breast	NULL
cancer	NULL
following	NULL
surgery	NULL
.	NULL

Sera	NULL
were	NULL
diluted	NULL
1:2	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
subjected	NULL
to	NULL
ultrafiltration	NULL
through	NULL
Amicon	NULL
CF	NULL
25	NULL
Centriflow	NULL
cones	NULL
(	NULL
Amicon	NULL
,	NULL
Danvers	NULL
,	NULL
MA	NULL
,	NULL
USA	NULL
)	NULL
for	NULL
15	NULL
min	NULL
at	NULL
800g	NULL
(	NULL
mol	NULL
.	NULL

wt	NULL
cut-off	NULL
point	NULL
25	NULL
kDa	NULL
)	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

PBMCs	NULL
were	NULL
isolated	NULL
as	NULL
described	NULL
previously	NULL
and	NULL
resuspended	NULL
to	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
x	NULL
10°	NULL
lymphocytes	NULL
per	NULL
ml	NULL
of	NULL
supplemented	NULL
RPMI-1640	NULL
.	NULL

Approximately	NULL
10°	NULL
PBMCs	NULL
per	NULL
well	NULL
were	NULL
cultured	NULL
with	NULL
100	NULL
pul	NULL
of	NULL
either	NULL
unseparated	NULL
sera	NULL
or	NULL
their	NULL
low	NULL
or	NULL
high	NULL
molecular	NULL
weight	NULL
fractions	NULL
in	NULL
final	NULL
dilutions	NULL
of	NULL
1:10	NULL
or	NULL
1:100	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Subsequently	NULL
,	NULL
PBMCs	NULL
were	NULL
stimulated	NULL
with	NULL
20	NULL
ul	NULL
of	NULL
PHA	NULL
(	NULL
HA	NULL
15	NULL
,	NULL
Murex	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
4	NULL
days	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
containing	NULL
5	NULL
%	NULL
carbon	NULL
dioxide	NULL
.	NULL

Statistical	NULL
methods	NULL
If	NULL
not	NULL
specified	NULL
otherwise	NULL
,	NULL
data	NULL
are	NULL
presented	NULL
as	NULL
mean	NULL
+	NULL
s.d	NULL
.	NULL

Statistics	NULL
were	NULL
done	NULL
by	NULL
X	NULL
``	NULL
and	NULL
Student	NULL
's	NULL
r-test	NULL
for	NULL
paired	NULL
data	NULL
.	NULL

Results	NULL
Mitogenic	NULL
stimulation	NULL
with	NULL
PHA	NULL
in	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
Table	NULL
I1	NULL
shows	NULL
the	NULL
results	NULL
of	NULL
assays	NULL
evaluating	NULL
PHA	NULL
stimulation	NULL
of	NULL
PBMCs	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
stage	NULL
I-III	NULL
breast	NULL
cancer	NULL
at	NULL
the	NULL
time	NULL
of	NULL
their	NULL
diagnosis	NULL
.	NULL

In	NULL
general	NULL
,	NULL
PBMCs	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
had	NULL
a	NULL
significantly	NULL
lower	NULL
proliferative	NULL
rate	NULL
in	NULL
response	NULL
to	NULL
PHA	NULL
than	NULL
those	NULL
from	NULL
healthy	NULL
control	NULL
individuals	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
this	NULL
decrease	NULL
in	NULL
mitogenic	NULL
stimulation	NULL
depended	NULL
on	NULL
the	NULL
stage	NULL
of	NULL
the	NULL
disease	NULL
,	NULL
i.e	NULL
.	NULL

a	NULL
clear	NULL
correlation	NULL
between	NULL
the	NULL
stage	NULL
of	NULL
the	NULL
disease	NULL
and	NULL
the	NULL
level	NULL
of	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
in	NULL
response	NULL
to	NULL
PHA	NULL
was	NULL
found	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
between	NULL
all	NULL
stages	NULL
of	NULL
the	NULL
disease	NULL
,	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Correlation	NULL
of	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
PBMC	NULL
with	NULL
other	NULL
clinical	NULL
parameters	NULL
in	NULL
breast	NULL
cancer	NULL
Table	NULL
II	NULL
shows	NULL
that	NULL
a	NULL
clear	NULL
correlation	NULL
of	NULL
the	NULL
PHA-induced	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
was	NULL
found	NULL
with	NULL
tumour	NULL
size	NULL
(	NULL
P	NULL
<	NULL
0.0035	NULL
)	NULL
and	NULL
the	NULL
number	NULL
of	NULL
involved	NULL
lymph	NULL
nodes	NULL
(	NULL
P	NULL
<	NULL
0.003	NULL
)	NULL
,	NULL
but	NULL
not	NULL
with	NULL
Table	NULL
I	NULL
_	NULL
PHA-stimulation	NULL
in	NULL
patients	NULL
with	NULL
stage	NULL
I-III	NULL
breast	NULL
cancer	NULL
at	NULL
the	NULL
time	NULL
of	NULL
diagnosis	NULL
and	NULL
in	NULL
healthy	NULL
controls	NULL
n	NULL
c.p.m	NULL
.	NULL

*	NULL
P-value	NULL
All	NULL
breast	NULL
cancer	NULL
patients	NULL
-	NULL
90	NULL
41.5	NULL
£	NULL
12.5	NULL
<	NULL
0.001	NULL
``	NULL
Stage	NULL
I	NULL
8	NULL
52.7	NULL
+	NULL
8.2	NULL
<	NULL
0.001	NULL
Stage	NULL
II	NULL
53	NULL
44.7	NULL
+	NULL
11.2	NULL
<	NULL
0.001	NULL
Stage	NULL
III	NULL
29	NULL
32.5	NULL
£	NULL
10.3	NULL
<	NULL
0.001	NULL
Healthy	NULL
controls	NULL
60	NULL
92.4	NULL
+	NULL
16.4	NULL
*Counts	NULL
per	NULL
minute	NULL
in	NULL
PBMC	NULL
stimulation	NULL
assays	NULL
using	NULL
PHA	NULL
.	NULL

``	NULL
Versus	NULL
data	NULL
obtained	NULL
in	NULL
healthy	NULL
controls	NULL
.	NULL

Table	NULL
II	NULL
Correlation	NULL
of	NULL
mitogenic	NULL
stimulation	NULL
measured	NULL
preoperatively	NULL
with	NULL
other	NULL
clinical	NULL
parameters	NULL
c.p.m	NULL
.	NULL

*	NULL
P-value	NULL
Tumour	NULL
size	NULL
(	NULL
cm	NULL
)	NULL
<	NULL
2	NULL
45.3	NULL
£	NULL
12.4	NULL
0.0035	NULL
-	NULL
>	NULL
2	NULL
31.4	NULL
£	NULL
10.0	NULL
Lymph	NULL
nodes	NULL
negative	NULL
49.7	NULL
%	NULL
11.6	NULL
0.003	NULL
positive	NULL
32.9	NULL
£	NULL
12.8	NULL
Oestrogen	NULL
receptor	NULL
(	NULL
ER	NULL
)	NULL
ER	NULL
positive	NULL
40.2	NULL
+	NULL
14.2	NULL
0.011	NULL
ER	NULL
negative	NULL
36.7	NULL
£	NULL
14.0	NULL
Progesterone	NULL
receptor	NULL
(	NULL
PgR	NULL
)	NULL
PgR	NULL
positive	NULL
40.1	NULL
+	NULL
12.6	NULL
0.016	NULL
PgR	NULL
negative	NULL
36.9	NULL
£	NULL
9.8	NULL
Menopausal	NULL
status	NULL
Premenopausal	NULL
35.3	NULL
£	NULL
10.0	NULL
NS®°	NULL
Post-menopausal	NULL
41.2	NULL
£	NULL
13.4	NULL
*Counts	NULL
per	NULL
minute	NULL
in	NULL
PBMC	NULL
stimulation	NULL
assays	NULL
using	NULL
PHA	NULL
.	NULL

``	NULL
Not	NULL
significant	NULL
.	NULL

1293	NULL
1294	NULL
PHA-stimulation	NULL
in	NULL
breast	NULL
cancer	NULL
Ch	NULL
Wiltschke	NULL
et	NULL
al	NULL
hormone	NULL
receptor	NULL
status	NULL
(	NULL
oestrogen	NULL
or	NULL
progesterone	NULL
receptor	NULL
)	NULL
or	NULL
age	NULL
.	NULL

Influence	NULL
of	NULL
adjuvant	NULL
therapy	NULL
upon	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
PBMCs	NULL
As	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
,	NULL
adjuvant	NULL
chemotherapy	NULL
with	NULL
CMF	NULL
reduced	NULL
mitogenic	NULL
stimulation	NULL
in	NULL
patients	NULL
with	NULL
stage	NULL
I-III	NULL
breast	NULL
cancer	NULL
significantly	NULL
.	NULL

While	NULL
PBMCs	NULL
derived	NULL
from	NULL
all	NULL
patients	NULL
who	NULL
received	NULL
adjuvant	NULL
CMF	NULL
treatment	NULL
showed	NULL
a	NULL
further	NULL
decrease	NULL
in	NULL
their	NULL
proliferation	NULL
in	NULL
response	NULL
to	NULL
PHA	NULL
after	NULL
6	NULL
months	NULL
of	NULL
therapy	NULL
as	NULL
compared	NULL
with	NULL
pretreatment	NULL
levels	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
,	NULL
neither	NULL
patients	NULL
under	NULL
endocrine	NULL
treatment	NULL
nor	NULL
patients	NULL
who	NULL
did	NULL
not	NULL
receive	NULL
any	NULL
adjuvant	NULL
drug	NULL
treatment	NULL
(	NULL
ie	NULL
.	NULL

patients	NULL
with	NULL
stage	NULL
I	NULL
disease	NULL
)	NULL
presented	NULL
with	NULL
similar	NULL
data	NULL
(	NULL
P	NULL
>	NULL
0.1	NULL
)	NULL
.	NULL

When	NULL
patients	NULL
who	NULL
received	NULL
adjuvant	NULL
CMF	NULL
treatment	NULL
were	NULL
studied	NULL
further	NULL
for	NULL
the	NULL
proliferative	NULL
rate	NULL
of	NULL
their	NULL
PBMCs	NULL
in	NULL
response	NULL
to	NULL
PHA	NULL
,	NULL
the	NULL
decrease	NULL
seen	NULL
after	NULL
6	NULL
months	NULL
had	NULL
vanished	NULL
after	NULL
an	NULL
additional	NULL
6	NULL
months	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
12	NULL
months	NULL
after	NULL
surgery	NULL
,	NULL
ie	NULL
.	NULL

6	NULL
months	NULL
after	NULL
termination	NULL
of	NULL
adjuvant	NULL
chemotherapy	NULL
with	NULL
CMF	NULL
,	NULL
PBMCs	NULL
from	NULL
patients	NULL
who	NULL
had	NULL
received	NULL
either	NULL
adjuvant	NULL
chemotherapy	NULL
or	NULL
adjuvant	NULL
endocrine	NULL
treatment	NULL
or	NULL
no	NULL
adjuvant	NULL
treatment	NULL
at	NULL
all	NULL
presented	NULL
with	NULL
similar	NULL
mean	NULL
proliferative	NULL
responses	NULL
in	NULL
response	NULL
to	NULL
PHA	NULL
.	NULL

Prognostic	NULL
value	NULL
of	NULL
PBMC	NULL
proliferation	NULL
12	NULL
months	NULL
post-operatively	NULL
in	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
In	NULL
a	NULL
further	NULL
analysis	NULL
,	NULL
the	NULL
course	NULL
of	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
in	NULL
response	NULL
to	NULL
PHA	NULL
before	NULL
the	NULL
initiation	NULL
of	NULL
treatment	NULL
and	NULL
after	NULL
12	NULL
months	NULL
was	NULL
analysed	NULL
prospectively	NULL
and	NULL
put	NULL
into	NULL
context	NULL
with	NULL
disease	NULL
status	NULL
after	NULL
a	NULL
total	NULL
of	NULL
36	NULL
months	NULL
.	NULL

Twelve	NULL
months	NULL
after	NULL
surgery	NULL
,	NULL
82	NULL
patients	NULL
had	NULL
remained	NULL
without	NULL
evidence	NULL
of	NULL
disease	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
clinical	NULL
means	NULL
.	NULL

Of	NULL
these	NULL
patients	NULL
,	NULL
15	NULL
showed	NULL
progressive	NULL
disease	NULL
after	NULL
36	NULL
months	NULL
,	NULL
whereas	NULL
67	NULL
patients	NULL
had	NULL
remained	NULL
disease	NULL
free	NULL
.	NULL

Owing	NULL
to	NULL
a	NULL
great	NULL
variability	NULL
between	NULL
the	NULL
patients	NULL
,	NULL
the	NULL
absolute	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
PBMCs	NULL
assessed	NULL
neither	NULL
preoperatively	NULL
nor	NULL
after	NULL
12	NULL
months	NULL
showed	NULL
significant	NULL
prognostic	NULL
relevance	NULL
.	NULL

Nevertheless	NULL
,	NULL
when	NULL
the	NULL
change	NULL
in	NULL
lymphocyte	NULL
proliferation	NULL
after	NULL
this	NULL
mitogenic	NULL
stimulation	NULL
was	NULL
compared	NULL
with	NULL
the	NULL
clinical	NULL
outcome	NULL
after	NULL
3	NULL
years	NULL
,	NULL
a	NULL
significant	NULL
correlation	NULL
was	NULL
seen	NULL
.	NULL

Patients	NULL
who	NULL
were	NULL
to	NULL
remain	NULL
in	NULL
complete	NULL
remission	NULL
for	NULL
36	NULL
months	NULL
showed	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
proliferative	NULL
responses	NULL
of	NULL
their	NULL
PBMCs	NULL
in	NULL
response	NULL
to	NULL
PHA	NULL
after	NULL
12	NULL
months	NULL
of	NULL
15.9	NULL
+	NULL
24.7	NULL
%	NULL
,	NULL
whereas	NULL
patients	NULL
with	NULL
future	NULL
progressive	NULL
disease	NULL
showed	NULL
a	NULL
further	NULL
decline	NULL
from	NULL
their	NULL
initial	NULL
level	NULL
of	NULL
proliferation	NULL
by	NULL
26.5	NULL
£	NULL
14.1	NULL
%	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

This	NULL
pattern	NULL
was	NULL
found	NULL
in	NULL
patients	NULL
with	NULL
various	NULL
initial	NULL
stages	NULL
of	NULL
breast	NULL
cancer	NULL
(	NULL
Table	NULL
III	NULL
)	NULL
and	NULL
was	NULL
independent	NULL
of	NULL
the	NULL
kind	NULL
of	NULL
adjuvant	NULL
treatment	NULL
(	NULL
i.e	NULL
.	NULL

chemotherapy	NULL
,	NULL
endocrine	NULL
therapy	NULL
or	NULL
both	NULL
)	NULL
.	NULL

70-w	NULL
g	NULL
*|-o	NULL
3	NULL
Ld	NULL
‘	NULL
0	NULL
i-X	NULL
E	NULL
30|-a	NULL
°	NULL
20|-10	NULL
o	NULL
1	NULL
|	NULL
1	NULL
1	NULL
__	NULL
]	NULL
0	NULL
6	NULL
12	NULL
36	NULL
Months	NULL
after	NULL
operation	NULL
Figure	NULL
1	NULL
-	NULL
Influence	NULL
of	NULL
adjuvant	NULL
therapy	NULL
upon	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
PBMCs	NULL
.	NULL

c.p.m	NULL
.	NULL

,	NULL
counts	NULL
per	NULL
min	NULL
;	NULL
--	NULL
,	NULL
adjuvant	NULL
endocrine	NULL
therapy	NULL
-	NULL
(	NULL
tamoxifen	NULL
)	NULL
;	NULL
_	NULL
...	NULL
,	NULL
CT	NULL
-	NULL
adjuvant	NULL
-	NULL
chemotherapy	NULL
(	NULL
CMF	NULL
=	NULL
cyclophosphamide	NULL
.	NULL

methotrexate	NULL
.	NULL

fluouracil	NULL
)	NULL
;	NULL
--	NULL
-	NULL
.	NULL

no	NULL
adjuvant	NULL
therapy	NULL
.	NULL

Influence	NULL
of	NULL
patients	NULL
'	NULL
sera	NULL
upon	NULL
PBMC	NULL
proliferation	NULL
In	NULL
order	NULL
to	NULL
evaluate	NULL
the	NULL
possibility	NULL
of	NULL
a	NULL
soluble	NULL
factor	NULL
secreted	NULL
by	NULL
the	NULL
tumour	NULL
or	NULL
other	NULL
soluble	NULL
factors	NULL
present	NULL
in	NULL
the	NULL
sera	NULL
of	NULL
patients	NULL
with	NULL
metastatic	NULL
breast	NULL
cancer	NULL
,	NULL
PBMC	NULL
proliferation	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
sera	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
untreated	NULL
metastatic	NULL
breast	NULL
cancer	NULL
.	NULL

Although	NULL
there	NULL
was	NULL
a	NULL
tendency	NULL
in	NULL
data	NULL
from	NULL
which	NULL
one	NULL
could	NULL
suspect	NULL
a	NULL
suppressive	NULL
influence	NULL
of	NULL
the	NULL
diluting	NULL
agent	NULL
itself	NULL
,	NULL
there	NULL
was	NULL
no	NULL
significant	NULL
difference	NULL
between	NULL
PHA	NULL
stimulation	NULL
of	NULL
PBMCs	NULL
with	NULL
or	NULL
without	NULL
control	NULL
sera	NULL
in	NULL
different	NULL
dilutions	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
sera	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
untreated	NULL
metastatic	NULL
breast	NULL
cancer	NULL
in	NULL
contrast	NULL
significantly	NULL
inhibited	NULL
the	NULL
proliferation	NULL
of	NULL
control	NULL
PBMCs	NULL
in	NULL
a	NULL
dilution-dependent	NULL
manner	NULL
(	NULL
serum	NULL
dilution	NULL
1:10	NULL
,	NULL
P	NULL
<	NULL
0.001	NULL
;	NULL
1:100	NULL
,	NULL
P	NULL
>	NULL
0.1	NULL
)	NULL
.	NULL

Table	NULL
IV	NULL
shows	NULL
the	NULL
results	NULL
of	NULL
two	NULL
representative	NULL
experiments	NULL
out	NULL
of	NULL
the	NULL
performed	NULL
six	NULL
assays	NULL
.	NULL

Table	NULL
V	NULL
shows	NULL
the	NULL
successful	NULL
enrichment	NULL
by	NULL
ultracentrifugation	NULL
of	NULL
the	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
responsible	NULL
for	NULL
the	NULL
suppression	NULL
of	NULL
PBMC	NULL
proliferation	NULL
in	NULL
the	NULL
protein	NULL
fraction	NULL
below	NULL
25	NULL
kDa	NULL
.	NULL

This	NULL
serum	NULL
preparation	NULL
resulted	NULL
in	NULL
the	NULL
most	NULL
effective	NULL
suppression	NULL
of	NULL
PHA	NULL
stimulation	NULL
which	NULL
could	NULL
not	NULL
be	NULL
reversed	NULL
by	NULL
dilution	NULL
(	NULL
Table	NULL
v	NULL
)	NULL
.	NULL

Table	NULL
HI	NULL
Correlation	NULL
of	NULL
clinical	NULL
course	NULL
with	NULL
changes	NULL
in	NULL
PHA	NULL
induced	NULL
stimulation	NULL
of	NULL
PBMCs	NULL
(	NULL
preoperative	NULL
values	NULL
compared	NULL
with	NULL
data	NULL
obtained	NULL
after	NULL
12	NULL
months	NULL
)	NULL
in	NULL
patients	NULL
with	NULL
stage	NULL
I-III	NULL
breast	NULL
cancer	NULL
with	NULL
complete	NULL
remission	NULL
after	NULL
36	NULL
months	NULL
(	NULL
n=	NULL
82	NULL
)	NULL
Change	NULL
in	NULL
mitogenic	NULL
Disease	NULL
status	NULL
stimulation	NULL
Fisher	NULL
's	NULL
exact	NULL
Group	NULL
at	NULL
36	NULL
months	NULL
-	NULL
Increase	NULL
Decrease	NULL
test	NULL
(	NULL
two-tailed	NULL
)	NULL
Total	NULL
CR	NULL
9	NULL
58	NULL
<	NULL
0.0001	NULL
PD	NULL
14	NULL
1	NULL
Stage	NULL
I	NULL
CR	NULL
2	NULL
6	NULL
PD	NULL
-	NULL
II	NULL
CR	NULL
5	NULL
39	NULL
0.0027	NULL
PD	NULL
4	NULL
1	NULL
HHI	NULL
CR	NULL
2	NULL
13	NULL
<	NULL
0.0001	NULL
PD	NULL
10	NULL
Overall	NULL
sensitivity	NULL
,	NULL
93.30	NULL
%	NULL
;	NULL
overall	NULL
specificity	NULL
,	NULL
86.70	NULL
%	NULL
;	NULL
positive	NULL
predictive	NULL
value	NULL
,	NULL
0.6087	NULL
;	NULL
Negative	NULL
predictive	NULL
value	NULL
.	NULL

0.9831	NULL
.	NULL

*Mitogenic	NULL
stimulation	NULL
with	NULL
phytohaemagglutinin	NULL
.	NULL

Table	NULL
IV	NULL
Influence	NULL
of	NULL
sera	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
untreated	NULL
metastatic	NULL
breast	NULL
cancer	NULL
upon	NULL
PHA-induced	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
derived	NULL
from	NULL
healthy	NULL
control	NULL
individuals	NULL
Experiment	NULL
Serum	NULL
Dilution	NULL
c.p.m*	NULL
1	NULL
0	NULL
82.6	NULL
+	NULL
10.5	NULL
Control	NULL
1:10	NULL
86.8	NULL
+	NULL
6.1	NULL
1:100	NULL
78.2	NULL
£	NULL
4.0	NULL
Patient	NULL
1:10	NULL
31.6	NULL
*+	NULL
7.4	NULL
1:100	NULL
85.8	NULL
£	NULL
4.5	NULL
2	NULL
0	NULL
102.3	NULL
+	NULL
11.8	NULL
Control	NULL
1:10	NULL
94.7	NULL
+	NULL
10.5	NULL
1:100	NULL
85.9	NULL
£	NULL
5.7	NULL
Patient	NULL
1:10	NULL
27.2	NULL
£	NULL
7.2	NULL
1:100	NULL
95.0	NULL
£	NULL
9.9	NULL
*Counts	NULL
per	NULL
minute	NULL
in	NULL
PBMC	NULL
stimulation	NULL
assays	NULL
using	NULL
PHA	NULL
.	NULL

Table	NULL
V	NULL
Characterisation	NULL
of	NULL
the	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
present	NULL
in	NULL
sera	NULL
of	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
which	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
PBMC	NULL
proliferation	NULL
Number	NULL
of	NULL
experiments	NULL
Serum	NULL
fraction	NULL
Dilution	NULL
c.p.m	NULL
.	NULL

4	NULL
Control	NULL
sera	NULL
,	NULL
1:10	NULL
75.8	NULL
£	NULL
14.3	NULL
unfractionated	NULL
1:100	NULL
82.3	NULL
+	NULL
15.9	NULL
6	NULL
Patients	NULL
'	NULL
sera	NULL
.	NULL

1:10	NULL
36.7	NULL
£	NULL
8.3	NULL
unfractionated	NULL
1:100	NULL
44.7	NULL
+	NULL
7.6	NULL
6	NULL
Patients	NULL
'	NULL
sera	NULL
1:10	NULL
35.9	NULL
£	NULL
7.0	NULL
>	NULL
25	NULL
kDa	NULL
1:100	NULL
40.3	NULL
+	NULL
9.4	NULL
6	NULL
Patients	NULL
'	NULL
sera	NULL
1:10	NULL
14.3	NULL
£	NULL
3.0	NULL
<	NULL
25	NULL
kDa	NULL
1:100	NULL
10.8	NULL
+	NULL
7.4	NULL
Correlation	NULL
of	NULL
the	NULL
proliferative	NULL
status	NULL
of	NULL
PBMCs	NULL
in	NULL
response	NULL
to	NULL
PHA	NULL
with	NULL
the	NULL
clinical	NULL
status	NULL
after	NULL
3	NULL
years	NULL
The	NULL
data	NULL
presented	NULL
in	NULL
Table	NULL
III	NULL
show	NULL
that	NULL
.	NULL

of	NULL
59	NULL
patients	NULL
who	NULL
presented	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
proliferative	NULL
ability	NULL
of	NULL
their	NULL
PBMCs	NULL
to	NULL
PHA	NULL
when	NULL
preoperative	NULL
data	NULL
and	NULL
values	NULL
obtained	NULL
after	NULL
12	NULL
months	NULL
were	NULL
compared	NULL
.	NULL

58	NULL
(	NULL
98	NULL
%	NULL
)	NULL
remained	NULL
in	NULL
complete	NULL
remission	NULL
for	NULL
a	NULL
total	NULL
of	NULL
3	NULL
years	NULL
.	NULL

In	NULL
contrast	NULL
.	NULL

of	NULL
23	NULL
patients	NULL
with	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
proliferation	NULL
of	NULL
their	NULL
PBMCs	NULL
in	NULL
response	NULL
to	NULL
PHA	NULL
within	NULL
12	NULL
months	NULL
.	NULL

only	NULL
nine	NULL
(	NULL
39	NULL
%	NULL
:	NULL
P	NULL
<	NULL
0.0001	NULL
)	NULL
remained	NULL
in	NULL
complete	NULL
remission	NULL
for	NULL
3	NULL
years	NULL
,	NULL
whereas	NULL
the	NULL
remaining	NULL
14	NULL
patients	NULL
(	NULL
61	NULL
%	NULL
)	NULL
developed	NULL
metastatic	NULL
disease	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
III	NULL
the	NULL
correlation	NULL
remains	NULL
significant	NULL
when	NULL
adjusted	NULL
to	NULL
disease	NULL
stage	NULL
(	NULL
stage	NULL
II	NULL
.	NULL

P=0.0027	NULL
:	NULL
stage	NULL
III	NULL
.	NULL

P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

These	NULL
data	NULL
result	NULL
in	NULL
an	NULL
overall	NULL
sensitivity	NULL
of	NULL
93.3	NULL
%	NULL
and	NULL
an	NULL
overall	NULL
specificity	NULL
of	NULL
86.7	NULL
%	NULL
.	NULL

Adjusting	NULL
for	NULL
stage	NULL
did	NULL
not	NULL
alter	NULL
estimates	NULL
.	NULL

Thus	NULL
.	NULL

PHA	NULL
stimulation	NULL
studied	NULL
longitudinally	NULL
constituted	NULL
an	NULL
important	NULL
new	NULL
parameter	NULL
.	NULL

Discussion	NULL
The	NULL
present	NULL
study	NULL
was	NULL
performed	NULL
in	NULL
order	NULL
to	NULL
analyse	NULL
prospectively	NULL
and	NULL
longitudinally	NULL
the	NULL
course	NULL
of	NULL
PHA-induced	NULL
stimulation	NULL
of	NULL
PBMCs	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
during	NULL
and	NULL
after	NULL
adjuvant	NULL
chemotherapy	NULL
or	NULL
endocrine	NULL
treatment	NULL
.	NULL

Moreover	NULL
.	NULL

we	NULL
studied	NULL
whether	NULL
the	NULL
results	NULL
from	NULL
assays	NULL
investigating	NULL
PHA-induced	NULL
stimulation	NULL
of	NULL
PBMC	NULL
had	NULL
a	NULL
prognostic	NULL
and	NULL
predictive	NULL
value	NULL
for	NULL
the	NULL
further	NULL
course	NULL
of	NULL
breast	NULL
cancer	NULL
.	NULL

In	NULL
following	NULL
these	NULL
aims	NULL
,	NULL
blood	NULL
samples	NULL
were	NULL
obtained	NULL
from	NULL
each	NULL
patient	NULL
before	NULL
surgery	NULL
and	NULL
6	NULL
as	NULL
well	NULL
as	NULL
12	NULL
months	NULL
thereafter	NULL
.	NULL

Independent	NULL
of	NULL
the	NULL
current	NULL
investigational	NULL
protocol	NULL
.	NULL

patients	NULL
had	NULL
been	NULL
randomised	NULL
after	NULL
surgery	NULL
to	NULL
receive	NULL
either	NULL
adjuvant	NULL
chemotherapy	NULL
according	NULL
to	NULL
the	NULL
CMF	NULL
protocol	NULL
or	NULL
tamoxifen	NULL
or	NULL
both	NULL
(	NULL
EBCTCG	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

It	NULL
was	NULL
found	NULL
tht	NULL
PHA-induced	NULL
stimulation	NULL
of	NULL
PBMCs	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
before	NULL
surgery	NULL
was	NULL
significantly	NULL
lower	NULL
than	NULL
in	NULL
PBMCs	NULL
from	NULL
healthy	NULL
control	NULL
individuals	NULL
and	NULL
correlated	NULL
with	NULL
the	NULL
stage	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

including	NULL
tumour	NULL
size	NULL
and	NULL
lymph	NULL
node	NULL
status	NULL
.	NULL

i.e	NULL
.	NULL

the	NULL
tumour	NULL
burden	NULL
.	NULL

Although	NULL
a	NULL
transient	NULL
drop	NULL
in	NULL
PHA-induced	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
derived	NULL
from	NULL
patients	NULL
undergoing	NULL
CMF	NULL
treatment	NULL
was	NULL
noted	NULL
.	NULL

12	NULL
months	NULL
after	NULL
surgery	NULL
the	NULL
mean	NULL
results	NULL
of	NULL
PBMC	NULL
proliferation	NULL
assays	NULL
were	NULL
similar	NULL
in	NULL
all	NULL
patient	NULL
groups	NULL
(	NULL
i.e	NULL
.	NULL

those	NULL
6	NULL
months	NULL
after	NULL
termination	NULL
of	NULL
CMF	NULL
treatment	NULL
or	NULL
during	NULL
tamoxifen	NULL
therapy	NULL
or	NULL
both	NULL
)	NULL
.	NULL

However	NULL
.	NULL

also	NULL
at	NULL
this	NULL
point	NULL
of	NULL
time	NULL
.	NULL

data	NULL
obtained	NULL
in	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
were	NULL
significantly	NULL
lower	NULL
than	NULL
those	NULL
from	NULL
healthy	NULL
controls	NULL
.	NULL

as	NULL
reported	NULL
previously	NULL
by	NULL
other	NULL
authors	NULL
(	NULL
Whittaker	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1971	NULL
;	NULL
Stein	NULL
et	NULL
al..	NULL
1976	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
demonstrated	NULL
.	NULL

finally	NULL
that	NULL
,	NULL
irrespective	NULL
of	NULL
the	NULL
kind	NULL
of	NULL
adjuvant	NULL
treatment	NULL
.	NULL

two-thirds	NULL
of	NULL
patients	NULL
whose	NULL
PBMCs	NULL
showed	NULL
a	NULL
drop	NULL
in	NULL
their	NULL
PHA-induced	NULL
proliferation	NULL
within	NULL
1	NULL
year	NULL
experienced	NULL
rapid	NULL
recurrence	NULL
of	NULL
disease	NULL
.	NULL

This	NULL
fact	NULL
was	NULL
further	NULL
corroborated	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
breast	NULL
cancer	NULL
did	NULL
not	NULL
recur	NULL
within	NULL
the	NULL
observation	NULL
period	NULL
in	NULL
patients	NULL
whose	NULL
PBMCs	NULL
showed	NULL
an	NULL
increase	NULL
in	NULL
PHA-induced	NULL
proliferation	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
in	NULL
the	NULL
current	NULL
report	NULL
pose	NULL
a	NULL
series	NULL
of	NULL
questions	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
persistent	NULL
decrease	NULL
in	NULL
PHA-induced	NULL
proliferation	NULL
of	NULL
PBMCs	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
has	NULL
to	NULL
be	NULL
explained	NULL
.	NULL

Considering	NULL
our	NULL
data	NULL
there	NULL
could	NULL
be	NULL
several	NULL
reasons	NULL
for	NULL
this	NULL
finding	NULL
.	NULL

The	NULL
initial	NULL
decrease	NULL
in	NULL
lymphocyte	NULL
proliferation	NULL
could	NULL
be	NULL
due	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
tumour	NULL
and	NULL
its	NULL
influence	NULL
upon	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Such	NULL
assumptions	NULL
can	NULL
be	NULL
made	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
data	NULL
obtained	NULL
in	NULL
humans	NULL
with	NULL
cancer	NULL
as	NULL
well	NULL
as	NULL
in	NULL
experimental	NULL
animals	NULL
which	NULL
demonstrated	NULL
decreased	NULL
DTH	NULL
and	NULL
a	NULL
defect	NULL
in	NULL
lymphocyte	NULL
proliferation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
neoplastic	NULL
tissue	NULL
(	NULL
Stein	NULL
et	NULL
a/..	NULL
1976	NULL
;	NULL
Broder	NULL
et	NULL
al..	NULL
1978	NULL
;	NULL
Giuliano	NULL
er	NULL
al..	NULL
1979	NULL
)	NULL
.	NULL

Several	NULL
reasons	NULL
have	NULL
been	NULL
discussed	NULL
for	NULL
these	NULL
findings	NULL
.	NULL

including	NULL
defective	NULL
lymphokine	NULL
production	NULL
and	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
production	NULL
of	NULL
suppressor	NULL
factors	NULL
by	NULL
the	NULL
tumour	NULL
(	NULL
Whittaker	NULL
er	NULL
a/..	NULL
PHA-stimulation	NULL
in	NULL
breast	NULL
cancer	NULL
Ch	NULL
Wiltschke	NULL
et	NULL
al	NULL
1971	NULL
;	NULL
Nimberg	NULL
et	NULL
al..	NULL
1975	NULL
;	NULL
North	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
;	NULL
Mizoguchi	NULL
et	NULL
al..	NULL
1992	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
by	NULL
other	NULL
investigators	NULL
(	NULL
Whittaker	NULL
et	NULL
al..	NULL
1971	NULL
;	NULL
Nimberg	NULL
et	NULL
al..	NULL
1975	NULL
;	NULL
Giuliano	NULL
et	NULL
al..	NULL
1979	NULL
;	NULL
North	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
;	NULL
Mizoguchi	NULL
et	NULL
al..	NULL
1992	NULL
)	NULL
as	NULL
well	NULL
as	NULL
our	NULL
data	NULL
would	NULL
favour	NULL
the	NULL
second	NULL
possibility	NULL
.	NULL

as	NULL
the	NULL
exogenous	NULL
addition	NULL
of	NULL
recombinant	NULL
interleukin	NULL
2	NULL
to	NULL
cultures	NULL
of	NULL
lymphocytes	NULL
derived	NULL
from	NULL
patients	NULL
who	NULL
had	NULL
presented	NULL
with	NULL
defective	NULL
proliferation	NULL
previously	NULL
in	NULL
our	NULL
experiments	NULL
did	NULL
not	NULL
have	NULL
any	NULL
enhancing	NULL
influence	NULL
upon	NULL
lymphocyte	NULL
function	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
.	NULL

the	NULL
addition	NULL
of	NULL
sera	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
metastatic	NULL
breast	NULL
cancer	NULL
to	NULL
lymphocytes	NULL
derived	NULL
from	NULL
healthy	NULL
control	NULL
individuals	NULL
produced	NULL
a	NULL
significant	NULL
decrease	NULL
in	NULL
PHA-induced	NULL
proliferation	NULL
,	NULL
thus	NULL
suggesting	NULL
the	NULL
presence	NULL
of	NULL
one	NULL
or	NULL
more	NULL
suppressive	NULL
factors	NULL
of	NULL
a	NULL
molecular	NULL
weight	NULL
below	NULL
25	NULL
kDa	NULL
.	NULL

Although	NULL
this	NULL
explanation	NULL
could	NULL
be	NULL
also	NULL
considered	NULL
for	NULL
the	NULL
finding	NULL
of	NULL
a	NULL
decrease	NULL
in	NULL
lymphocyte	NULL
proliferation	NULL
in	NULL
patients	NULL
who	NULL
were	NULL
to	NULL
develop	NULL
metastatic	NULL
disease	NULL
within	NULL
the	NULL
subsequent	NULL
2	NULL
years	NULL
,	NULL
additional	NULL
variables	NULL
,	NULL
including	NULL
the	NULL
induction	NULL
of	NULL
suppressor	NULL
cells	NULL
by	NULL
the	NULL
emerging	NULL
tumour	NULL
(	NULL
Yu	NULL
et	NULL
a/..	NULL
1977	NULL
;	NULL
North	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
)	NULL
or	NULL
an	NULL
alteration	NULL
in	NULL
signal	NULL
transduction	NULL
molecules	NULL
(	NULL
Mizoguchi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
must	NULL
be	NULL
considered	NULL
.	NULL

The	NULL
problem	NULL
could	NULL
be	NULL
further	NULL
aggravated	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
adjuvant	NULL
cytostatic	NULL
treatment	NULL
with	NULL
CMF	NULL
has	NULL
previously	NULL
been	NULL
demonstrated	NULL
in	NULL
studies	NULL
in	NULL
this	NULL
laboratory	NULL
to	NULL
lead	NULL
to	NULL
a	NULL
prolonged	NULL
defect	NULL
in	NULL
the	NULL
production	NULL
of	NULL
a	NULL
primary	NULL
immune	NULL
response	NULL
following	NULL
vaccination	NULL
(	NULL
Zielinski	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
and	NULL
lymphocyte	NULL
proliferation	NULL
(	NULL
Knogler	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
as	NULL
well	NULL
as	NULL
lymphokine	NULL
production	NULL
(	NULL
Zielinski	NULL
er	NULL
al..	NULL
1986	NULL
,	NULL
1989b	NULL
)	NULL
.	NULL

The	NULL
latter	NULL
aspects	NULL
also	NULL
constitute	NULL
the	NULL
most	NULL
likely	NULL
explanations	NULL
for	NULL
the	NULL
decrease	NULL
in	NULL
PHA-induced	NULL
lymphocyte	NULL
proliferation	NULL
under	NULL
immediate	NULL
CMF	NULL
therapy	NULL
seen	NULL
in	NULL
the	NULL
present	NULL
study	NULL
.	NULL

Clinically	NULL
,	NULL
the	NULL
decrease	NULL
in	NULL
lymphocyte	NULL
proliferation	NULL
in	NULL
two-thirds	NULL
of	NULL
patients	NULL
who	NULL
were	NULL
to	NULL
develop	NULL
metastases	NULL
within	NULL
the	NULL
relatively	NULL
near	NULL
future	NULL
clearly	NULL
constitutes	NULL
a	NULL
new	NULL
prognostic	NULL
tool	NULL
for	NULL
the	NULL
prediction	NULL
of	NULL
the	NULL
development	NULL
of	NULL
early	NULL
metastatic	NULL
disease	NULL
.	NULL

Nevertheless	NULL
,	NULL
owing	NULL
to	NULL
the	NULL
relatively	NULL
small	NULL
number	NULL
of	NULL
patients	NULL
and	NULL
short	NULL
follow-up	NULL
times	NULL
.	NULL

the	NULL
ultimate	NULL
prognostic	NULL
value	NULL
of	NULL
this	NULL
phenomenon	NULL
has	NULL
to	NULL
be	NULL
proven	NULL
in	NULL
a	NULL
larger	NULL
study	NULL
.	NULL

which	NULL
is	NULL
ongoing	NULL
in	NULL
our	NULL
institute	NULL
.	NULL

Although	NULL
previous	NULL
studies	NULL
on	NULL
a	NULL
similar	NULL
question	NULL
have	NULL
failed	NULL
to	NULL
find	NULL
such	NULL
a	NULL
prognostic	NULL
value	NULL
for	NULL
PHA	NULL
stimulation	NULL
(	NULL
Stein	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1976	NULL
;	NULL
Nordman	NULL
et	NULL
al..	NULL
1985	NULL
)	NULL
in	NULL
solid	NULL
tumours	NULL
.	NULL

it	NULL
is	NULL
an	NULL
accepted	NULL
predictive	NULL
parameter	NULL
in	NULL
Hodgkin	NULL
's	NULL
disease	NULL
(	NULL
Bjorkholm	NULL
er	NULL
al..	NULL
1982	NULL
;	NULL
Wedelin	NULL
er	NULL
al..	NULL
1982	NULL
)	NULL
.	NULL

However	NULL
.	NULL

the	NULL
lack	NULL
of	NULL
such	NULL
a	NULL
finding	NULL
in	NULL
patients	NULL
with	NULL
solid	NULL
tumours	NULL
may	NULL
be	NULL
due	NULL
to	NULL
the	NULL
heterogeneity	NULL
of	NULL
studied	NULL
patients	NULL
so	NULL
far	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
fact	NULL
is	NULL
surprising	NULL
,	NULL
as	NULL
immunological	NULL
variables	NULL
have	NULL
not	NULL
been	NULL
used	NULL
until	NULL
now	NULL
as	NULL
either	NULL
prognostic	NULL
tools	NULL
or	NULL
for	NULL
the	NULL
design	NULL
of	NULL
adjuvant	NULL
trials	NULL
.	NULL

However	NULL
,	NULL
several	NULL
studies	NULL
have	NULL
demonstrated	NULL
a	NULL
clear	NULL
association	NULL
of	NULL
lytic	NULL
effector	NULL
lymphocyte	NULL
function	NULL
and	NULL
such	NULL
established	NULL
prognostic	NULL
variables	NULL
as	NULL
tumour	NULL
load	NULL
(	NULL
Contesso	NULL
et	NULL
a/..	NULL
1989	NULL
)	NULL
.	NULL

oestrogen	NULL
receptor	NULL
status	NULL
(	NULL
Clark	NULL
er	NULL
al..	NULL
1988	NULL
)	NULL
and	NULL
amplification	NULL
of	NULL
the	NULL
HER-2neu	NULL
oncogene	NULL
(	NULL
Zeillinger	NULL
et	NULL
al..	NULL
1989	NULL
)	NULL
.	NULL

Although	NULL
further	NULL
studies	NULL
and	NULL
the	NULL
use	NULL
of	NULL
more	NULL
sophisticated	NULL
stimulants	NULL
of	NULL
lymphocyte	NULL
proliferation	NULL
than	NULL
the	NULL
widely	NULL
available	NULL
PHA	NULL
assay	NULL
including	NULL
the	NULL
use	NULL
of	NULL
anti-CD3	NULL
antibodies	NULL
will	NULL
have	NULL
to	NULL
corroborate	NULL
and	NULL
extend	NULL
our	NULL
results	NULL
.	NULL

the	NULL
results	NULL
presented	NULL
in	NULL
the	NULL
current	NULL
report	NULL
could	NULL
lead	NULL
to	NULL
such	NULL
clinical	NULL
consequences	NULL
as	NULL
lymphokine	NULL
treatment	NULL
or	NULL
the	NULL
repeated	NULL
use	NULL
of	NULL
a	NULL
series	NULL
of	NULL
adjuvant	NULL
cytostatic	NULL
therapies	NULL
in	NULL
expanded	NULL
time	NULL
intervals	NULL
or	NULL
in	NULL
selected	NULL
patients	NULL
who	NULL
fulfil	NULL
the	NULL
appropriate	NULL
immunological	NULL
criteria	NULL
.	NULL

Abbreviations	NULL
DTH	NULL
.	NULL

delayed-type	NULL
hypersensitivity	NULL
:	NULL
IL-2	NULL
.	NULL

interleukin	NULL
2	NULL
;	NULL
PBMC	NULL
.	NULL

peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
:	NULL
PHA	NULL
.	NULL

phytohaemagglutinin	NULL
:	NULL
CMF	NULL
.	NULL

cyclophosphamide	NULL
.	NULL

methotrexate	NULL
.	NULL

fluoruractl	NULL
;	NULL
ER	NULL
.	NULL

oestrogen	NULL
receptor	NULL
:	NULL
PgR	NULL
.	NULL

progesterone	NULL
receptor	NULL
.	NULL

Ackno	NULL
The	NULL
authors	NULL
thank	NULL
Dr	NULL
Susan	NULL
Hilsenbeck	NULL
for	NULL
assistance	NULL
in	NULL
statistical	NULL
analysis	NULL
and	NULL
Ms	NULL
Waclawa	NULL
Kalinowski	NULL
.	NULL

who	NULL
contributed	NULL
by	NULL
providing	NULL
expert	NULL
technical	NULL
assistance	NULL
.	NULL

1295	NULL
12	NULL
%	NULL
PHA-stimulation	NULL
in	NULL
breast	NULL
cancer	NULL
Ch	NULL
Wiltschke	NULL
et	NULL
af	NULL
References	NULL
BJORKHOLM	NULL
M.	NULL
WEDELIN	NULL
C.	NULL
HOLM	NULL
G	NULL
,	NULL
OGENSTAD	NULL
S.	NULL
JOHANSSON	NULL
B	NULL
AND	NULL
MELLSTEDT	NULL
T.	NULL
(	NULL
1982	NULL
)	NULL
.	NULL

Immune	NULL
status	NULL
of	NULL
untreated	NULL
patients	NULL
with	NULL
Hodgkin	NULL
's	NULL
disease	NULL
and	NULL
prognosis	NULL
.	NULL

Cancer	NULL
Treat	NULL
.	NULL

Rep..	NULL
66	NULL
,	NULL
701	NULL
.	NULL

BONADONNA	NULL
G.	NULL
ROSSI	NULL
A.	NULL
VALAGUSSA	NULL
P.	NULL
BANFI	NULL
A	NULL
AND	NULL
VERONESI	NULL
U	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
.	NULL

The	NULL
CMF	NULL
program	NULL
for	NULL
operable	NULL
breast	NULL
cancer	NULL
with	NULL
positive	NULL
axillary	NULL
nodes	NULL
.	NULL

Cancer	NULL
,	NULL
39	NULL
,	NULL
2904-2910	NULL
.	NULL

BRODER	NULL
S	NULL
AND	NULL
WALDMANN	NULL
TA	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
.	NULL

The	NULL
suppressor-cell	NULL
network	NULL
in	NULL
cancer	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
299	NULL
,	NULL
1335-1341	NULL
.	NULL

CLARK	NULL
GM	NULL
AND	NULL
MCGUIRE	NULL
WL	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Steroid	NULL
receptors	NULL
and	NULL
other	NULL
prognostic	NULL
factors	NULL
in	NULL
primary	NULL
breast	NULL
cancer	NULL
.	NULL

Oncology	NULL
,	NULL
15	NULL
(	NULL
Suppl	NULL
.	NULL

1	NULL
)	NULL
.	NULL

20-25	NULL
.	NULL

CONTESSO	NULL
G.	NULL
SACCANUJOTTI	NULL
G	NULL
AND	NULL
BONADONNA	NULL
G.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Tumor	NULL
grade	NULL
as	NULL
prognostic	NULL
factor	NULL
in	NULL
primary	NULL
breast	NULL
cancer	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
Clin	NULL
.	NULL

Oncol..	NULL
25	NULL
,	NULL
403-9	NULL
.	NULL

CUNNINGHAM-RUNDLES	NULL
S.	NULL
FILLIPA	NULL
DA	NULL
.	NULL

BRAUN	NULL
DW	NULL
.	NULL

ANTONELLI	NULL
P	NULL
AND	NULL
ASHIKARI	NULL
H.	NULL
(	NULL
1981	NULL
)	NULL
.	NULL

Natural	NULL
cytotoxicity	NULL
of	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
and	NULL
regional	NULL
lymph	NULL
node	NULL
cells	NULL
in	NULL
breast	NULL
cancer	NULL
in	NULL
women	NULL
.	NULL

J.	NULL
Natl	NULL
Cancer	NULL
Inst	NULL
.	NULL

,	NULL
67	NULL
,	NULL
585-590	NULL
.	NULL

EARLY	NULL
BREAST	NULL
CANCER	NULL
TRIALISTS	NULL
COLLABORATIVE	NULL
GROUP	NULL
(	NULL
EBCTCG	NULL
)	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Systemic	NULL
treatment	NULL
of	NULL
early	NULL
breast	NULL
cancer	NULL
by	NULL
hormonal	NULL
.	NULL

cytotoxic	NULL
.	NULL

or	NULL
immune	NULL
therapy	NULL
:	NULL
133	NULL
randomised	NULL
trials	NULL
involving	NULL
31.000	NULL
recurrences	NULL
and	NULL
24.000	NULL
deaths	NULL
among	NULL
75.000	NULL
women	NULL
.	NULL

Lancet	NULL
.	NULL

i	NULL
,	NULL
1-15	NULL
,	NULL
71-85	NULL
.	NULL

FEARON	NULL
ER	NULL
.	NULL

PARDOLL	NULL
DM	NULL
.	NULL

ITAYA	NULL
T.	NULL
GOLUMBEK	NULL
P.	NULL
LEVITSKY	NULL
HI	NULL
.	NULL

SIMONS	NULL
JW	NULL
.	NULL

KARASUYAMA	NULL
H.	NULL
VOGELSTEIN	NULL
B	NULL
AND	NULL
FROST	NULL
B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Interleukin-2	NULL
production	NULL
by	NULL
tumor	NULL
cell	NULL
bypasses	NULL
T	NULL
helper	NULL
function	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
an	NULL
antitumor	NULL
response	NULL
.	NULL

Cell	NULL
,	NULL
60	NULL
,	NULL
397-403	NULL
.	NULL

GIULIANO	NULL
AE	NULL
.	NULL

RANGEL	NULL
D.	NULL
GOLUB	NULL
SH	NULL
.	NULL

HOLMES	NULL
CE	NULL
AND	NULL
MORTON	NULL
DL	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
.	NULL

Serum-mediated	NULL
immunosuppression	NULL
in	NULL
lung	NULL
cancer	NULL
.	NULL

Cancer	NULL
.	NULL

43	NULL
,	NULL
917-924	NULL
.	NULL

KIRCHENER	NULL
H.	NULL
(	NULL
1978	NULL
)	NULL
.	NULL

Suppressor	NULL
cells	NULL
of	NULL
immune	NULL
reactivity	NULL
in	NULL
malignancy	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
.	NULL

14	NULL
,	NULL
453-459	NULL
.	NULL

KNOGLER	NULL
W.	NULL
KUBISTA	NULL
E	NULL
AND	NULL
ZIELINSKI	NULL
CC	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Prolonged	NULL
decrease	NULL
in	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
following	NULL
adjuvant	NULL
chemotherapy	NULL
,	NULL
but	NULL
not	NULL
under	NULL
tamoxifen	NULL
,	NULL
in	NULL
stage	NULL
II	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
J.	NULL
,	NULL
5	NULL
,	NULL
32-3	NULL
.	NULL

MIKI	NULL
J	NULL
,	NULL
AIGINGER	NULL
P.	NULL
CZERWENKA	NULL
K.	NULL
KUBISTA	NULL
E.	NULL
SALZER	NULL
H.	NULL
SEVELDA	NULL
P	NULL
,	NULL
SPONA	NULL
J.	NULL
STAFFEN	NULL
A	NULL
AND	NULL
ZIELINSKI	NULL
CC	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Adjuvant	NULL
tamoxifen	NULL
in	NULL
postmenopausal	NULL
stage	NULL
II	NULL
breast	NULL
cancer	NULL
five	NULL
years	NULL
on	NULL
.	NULL

Lancet	NULL
,	NULL
335	NULL
,	NULL
541-542	NULL
.	NULL

MIZOGUCHI	NULL
H.	NULL
O'SHEA	NULL
JJ	NULL
.	NULL

LONGO	NULL
DL	NULL
.	NULL

LOEFFLER	NULL
CM	NULL
,	NULL
MCVICAR	NULL
DW	NULL
AND	NULL
OCHOA	NULL
AC	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Alterations	NULL
in	NULL
signal	NULL
transduction	NULL
molecules	NULL
in	NULL
T	NULL
lymphocytes	NULL
from	NULL
tumor-bearing	NULL
mice	NULL
.	NULL

Science	NULL
,	NULL
.	NULL

258	NULL
,	NULL
1795-1798	NULL
.	NULL

NIMBERG	NULL
RB	NULL
.	NULL

GLASGOW	NULL
AH	NULL
.	NULL

MENZOIAN	NULL
JO	NULL
,	NULL
CONSTANTIAN	NULL
MB	NULL
.	NULL

COOPERBAND	NULL
SR.	NULL
MANNICK	NULL
JA	NULL
AND	NULL
SCHMID	NULL
K.	NULL
(	NULL
1975	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
an	NULL
immunosuppressive	NULL
peptide	NULL
fraction	NULL
from	NULL
the	NULL
serum	NULL
of	NULL
cancer	NULL
patients	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
35	NULL
,	NULL
1489-1494	NULL
.	NULL

NORDMAN	NULL
E.	NULL
LEHTO	NULL
I	NULL
AND	NULL
TOIVANEN	NULL
A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
.	NULL

Immune	NULL
functions	NULL
and	NULL
the	NULL
prognosis	NULL
of	NULL
patients	NULL
with	NULL
solid	NULL
tumours	NULL
.	NULL

Cancer	NULL
Immunol	NULL
.	NULL

Immunother..	NULL
20	NULL
,	NULL
38-42	NULL
.	NULL

NORTH	NULL
RJ	NULL
AND	NULL
BURSUKER	NULL
I	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
.	NULL

Generation	NULL
and	NULL
decay	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
to	NULL
a	NULL
progressive	NULL
fibrosarcoma	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med..	NULL
159	NULL
,	NULL
1295-1311	NULL
.	NULL

PENN	NULL
I	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
.	NULL

The	NULL
occurrence	NULL
of	NULL
cancer	NULL
in	NULL
immune	NULL
deficiencies	NULL
.	NULL

Curr	NULL
.	NULL

Prob	NULL
.	NULL

Cancer	NULL
.	NULL

6	NULL
(	NULL
10	NULL
)	NULL
.	NULL

1-64	NULL
.	NULL

PENN	NULL
I	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Cancer	NULL
is	NULL
long-term	NULL
hazard	NULL
of	NULL
immunosuppressive	NULL
therapy	NULL
.	NULL

J.	NULL
Autoimmunity	NULL
,	NULL
1	NULL
,	NULL
545-548	NULL
.	NULL

STEIN	NULL
JA	NULL
.	NULL

ADLER	NULL
A.	NULL
BEN	NULL
EFRAIM	NULL
S	NULL
AND	NULL
MAOR	NULL
M.	NULL
(	NULL
1976	NULL
)	NULL
.	NULL

Immunocompetence	NULL
,	NULL
.	NULL

immunosuppression	NULL
,	NULL
and	NULL
human	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
,	NULL
38	NULL
,	NULL
1171-1187	NULL
.	NULL

TICHATSCHEK	NULL
E.	NULL
ZIELINSKI	NULL
CD	NULL
.	NULL

MULLER	NULL
CH	NULL
.	NULL

SEVELDA	NULL
P.	NULL
KUBISTA	NULL
E.	NULL
CZERWENKA	NULL
K.	NULL
SPONA	NULL
J.	NULL
WOLF	NULL
H	NULL
AND	NULL
EIBL	NULL
MM	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Long-term	NULL
influence	NULL
of	NULL
adjuvant	NULL
therapeutic	NULL
measures	NULL
upon	NULL
natural	NULL
killer	NULL
cell	NULL
activity	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
Immunol	NULL
.	NULL

Immunother	NULL
.	NULL

,	NULL
27	NULL
,	NULL
278-283	NULL
.	NULL

UCHIDA	NULL
A	NULL
AND	NULL
HOSHINO	NULL
T.	NULL
(	NULL
1980	NULL
)	NULL
.	NULL

Clinical	NULL
studies	NULL
on	NULL
cell-mediated	NULL
immunity	NULL
in	NULL
patients	NULL
with	NULL
malignant	NULL
disease	NULL
.	NULL

Cancer	NULL
Immunol	NULL
.	NULL

Immunother	NULL
.	NULL

,	NULL
9	NULL
,	NULL
153-158	NULL
.	NULL

VOSE	NULL
BM	NULL
AND	NULL
MOORE	NULL
M.	NULL
(	NULL
1980	NULL
)	NULL
.	NULL

Heterogeneity	NULL
of	NULL
suppressor	NULL
of	NULL
mitogen	NULL
responsiveness	NULL
in	NULL
human	NULL
malignancy	NULL
.	NULL

Cancer	NULL
Immunol	NULL
.	NULL

Immunother	NULL
.	NULL

,	NULL
9	NULL
,	NULL
163-172	NULL
.	NULL

WEDELIN	NULL
C.	NULL
BJORKHOLM	NULL
M.	NULL
HOLM	NULL
G.	NULL
OGENSTAD	NULL
S.	NULL
JOHANSSON	NULL
B	NULL
AND	NULL
MELLSTEDT	NULL
H.	NULL
(	NULL
1982	NULL
)	NULL
.	NULL

Lymphocyte	NULL
function	NULL
in	NULL
untreated	NULL
Hodgkin	NULL
's	NULL
disease	NULL
:	NULL
an	NULL
important	NULL
predictor	NULL
of	NULL
prognosis	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
45	NULL
,	NULL
70	NULL
.	NULL

WHITE	NULL
D.	NULL
JONES	NULL
DB	NULL
.	NULL

COOKE	NULL
T	NULL
AND	NULL
KIRKHAM	NULL
N.	NULL
(	NULL
1982	NULL
)	NULL
.	NULL

Natural	NULL
killer	NULL
(	NULL
NK	NULL
)	NULL
activity	NULL
in	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
of	NULL
patients	NULL
with	NULL
benign	NULL
and	NULL
malignant	NULL
breast	NULL
disease	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
.	NULL

46	NULL
,	NULL
611-6	NULL
.	NULL

WHITTAKER	NULL
MG	NULL
,	NULL
REES	NULL
K	NULL
AND	NULL
CLARK	NULL
CG	NULL
.	NULL

(	NULL
1971	NULL
)	NULL
.	NULL

Reduced	NULL
lymphocyte	NULL
transformation	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Lancer	NULL
,	NULL
892-893	NULL
.	NULL

YU	NULL
A	NULL
,	NULL
WATTS	NULL
H.	NULL
JAFFE	NULL
N	NULL
AND	NULL
PARKMAN	NULL
R.	NULL
(	NULL
1977	NULL
)	NULL
.	NULL

Concomitant	NULL
presence	NULL
of	NULL
tumor-specific	NULL
cytotoxic	NULL
and	NULL
inhibitor	NULL
lymphocytes	NULL
in	NULL
patients	NULL
with	NULL
osteogenic	NULL
sarcoma	NULL
.	NULL

N.	NULL
Engl	NULL
J.	NULL
Med..	NULL
297	NULL
,	NULL
121-127	NULL
.	NULL

ZIELINSKI	NULL
CC	NULL
,	NULL
STULLER	NULL
I.	NULL
DORNER	NULL
F.	NULL
MULLER	NULL
C	NULL
AND	NULL
EIBL	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
.	NULL

Impaired	NULL
primary	NULL
but	NULL
not	NULL
secondary	NULL
immune	NULL
response	NULL
in	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
under	NULL
aduvant	NULL
therapy	NULL
.	NULL

Cancer	NULL
.	NULL

58	NULL
,	NULL
1648	NULL
.	NULL

ZEILLINGER	NULL
R	NULL
,	NULL
KURY	NULL
F.	NULL
CZERWENKA	NULL
K.	NULL
KUBISTA	NULL
E.	NULL
SLIUTZ	NULL
G	NULL
,	NULL
KNOGLER	NULL
W	NULL
,	NULL
HUBER	NULL
J.	NULL
ZIELINSKI	NULL
C.	NULL
REINER	NULL
G	NULL
,	NULL
JAKESZ	NULL
R.	NULL
STAFFEN	NULL
A.	NULL
REINER	NULL
A.	NULL
WRBA	NULL
F	NULL
AND	NULL
SPONA	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

HER-2	NULL
amplification	NULL
,	NULL
steroid	NULL
receptors	NULL
and	NULL
epidermal	NULL
growth	NULL
factor	NULL
receptor	NULL
in	NULL
primary	NULL
breast	NULL
cancer	NULL
.	NULL

Oncogene	NULL
,	NULL
4	NULL
,	NULL
109-112	NULL
.	NULL

ZIELINSKI	NULL
CC	NULL
,	NULL
TICHATSCHEK	NULL
E.	NULL
MULLER	NULL
C.	NULL
KALINOWSKA	NULL
w.	NULL
SEVELDA	NULL
P.	NULL
CZERWENKA	NULL
K.	NULL
KUBISTA	NULL
E	NULL
AND	NULL
SPONA	NULL
J	NULL
.	NULL

(	NULL
1989a	NULL
)	NULL
.	NULL

Association	NULL
of	NULL
increased	NULL
lytic	NULL
effector	NULL
cell	NULL
function	NULL
with	NULL
high	NULL
estrogen	NULL
receptor	NULL
levels	NULL
in	NULL
tumour-bearing	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
,	NULL
63	NULL
,	NULL
1985-1989	NULL
.	NULL

ZIELINSKI	NULL
CC	NULL
,	NULL
.	NULL

MULLER	NULL
C.	NULL
TICHATSCHEK	NULL
E	NULL
AND	NULL
AIGINGER	NULL
P.	NULL
(	NULL
19896	NULL
)	NULL
.	NULL

Decreased	NULL
production	NULL
of	NULL
soluble	NULL
interleukin	NULL
2	NULL
receptor	NULL
by	NULL
phytohaemagglutinin-stimulated	NULL
peripheral	NULL
mononuclear	NULL
cells	NULL
in	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
after	NULL
adjuvant	NULL
therapy	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
60	NULL
,	NULL
712-714	NULL
.	NULL

